195 related articles for article (PubMed ID: 25000246)
1. The targeted transduction of MMP-overexpressing tumor cells by ACPP-HPMA copolymer-coated adenovirus conjugates.
Li S; Chen J; Xu H; Long J; Xie X; Zhang Y
PLoS One; 2014; 9(7):e100670. PubMed ID: 25000246
[TBL] [Abstract][Full Text] [Related]
2. The transduction of Coxsackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus.
Wang CH; Chan LW; Johnson RN; Chu DS; Shi J; Schellinger JG; Lieber A; Pun SH
Biomaterials; 2011 Dec; 32(35):9536-45. PubMed ID: 21959008
[TBL] [Abstract][Full Text] [Related]
3. Tumor targeting of MMP-2/9 activatable cell-penetrating imaging probes is caused by tumor-independent activation.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
J Nucl Med; 2011 Feb; 52(2):279-86. PubMed ID: 21233187
[TBL] [Abstract][Full Text] [Related]
4. Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage.
Shi NQ; Gao W; Xiang B; Qi XR
Int J Nanomedicine; 2012; 7():1613-21. PubMed ID: 22619516
[TBL] [Abstract][Full Text] [Related]
5. In vivo biodistribution of radiolabeled MMP-2/9 activatable cell-penetrating peptide probes in tumor-bearing mice.
van Duijnhoven SM; Robillard MS; Nicolay K; Grüll H
Contrast Media Mol Imaging; 2015; 10(1):59-66. PubMed ID: 24823643
[TBL] [Abstract][Full Text] [Related]
6. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides.
Aguilera TA; Olson ES; Timmers MM; Jiang T; Tsien RY
Integr Biol (Camb); 2009 Jun; 1(5-6):371-81. PubMed ID: 20023744
[TBL] [Abstract][Full Text] [Related]
7. Tat-conjugated synthetic macromolecules facilitate cytoplasmic drug delivery to human ovarian carcinoma cells.
Nori A; Jensen KD; Tijerina M; Kopecková P; Kopecek J
Bioconjug Chem; 2003; 14(1):44-50. PubMed ID: 12526691
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapeutic drug delivery to cancer cells using a combination of folate targeting and tumor microenvironment-sensitive polypeptides.
Gao W; Xiang B; Meng TT; Liu F; Qi XR
Biomaterials; 2013 May; 34(16):4137-4149. PubMed ID: 23453200
[TBL] [Abstract][Full Text] [Related]
9. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer.
Olson ES; Aguilera TA; Jiang T; Ellies LG; Nguyen QT; Wong EH; Gross LA; Tsien RY
Integr Biol (Camb); 2009 Jun; 1(5-6):382-93. PubMed ID: 20023745
[TBL] [Abstract][Full Text] [Related]
10. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
Peng ZH; Kopeček J
J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human lung cancer cells by anti-p21Ras scFv mediated by the activatable cell-penetrating peptide.
Du Y; Lin X; Feng Q; Pan X; Song S; Yang J
Anticancer Drugs; 2022 Jan; 33(1):e562-e572. PubMed ID: 34338241
[TBL] [Abstract][Full Text] [Related]
12. Enhancing siRNA-based cancer therapy using a new pH-responsive activatable cell-penetrating peptide-modified liposomal system.
Xiang B; Jia XL; Qi JL; Yang LP; Sun WH; Yan X; Yang SK; Cao DY; Du Q; Qi XR
Int J Nanomedicine; 2017; 12():2385-2405. PubMed ID: 28405163
[TBL] [Abstract][Full Text] [Related]
13. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
14. A smart polymeric platform for multistage nucleus-targeted anticancer drug delivery.
Zhong J; Li L; Zhu X; Guan S; Yang Q; Zhou Z; Zhang Z; Huang Y
Biomaterials; 2015 Oct; 65():43-55. PubMed ID: 26142775
[TBL] [Abstract][Full Text] [Related]
15. Protease-Activable Cell-Penetrating Peptide-Protoporphyrin Conjugate for Targeted Photodynamic Therapy in Vivo.
Li SY; Cheng H; Qiu WX; Liu LH; Chen S; Hu Y; Xie BR; Li B; Zhang XZ
ACS Appl Mater Interfaces; 2015 Dec; 7(51):28319-29. PubMed ID: 26634784
[TBL] [Abstract][Full Text] [Related]
16. Dual targeting of integrin αvβ3 and matrix metalloproteinase-2 for optical imaging of tumors and chemotherapeutic delivery.
Crisp JL; Savariar EN; Glasgow HL; Ellies LG; Whitney MA; Tsien RY
Mol Cancer Ther; 2014 Jun; 13(6):1514-25. PubMed ID: 24737028
[TBL] [Abstract][Full Text] [Related]
17. [The design and enzymatic hydrolysis of activatable cell-penetrating peptide].
Wang PC; Qi XR
Yao Xue Xue Bao; 2010 Aug; 45(8):1048-51. PubMed ID: 21351594
[TBL] [Abstract][Full Text] [Related]
18. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
19. Imaging of MMP activity in postischemic cardiac remodeling using radiolabeled MMP-2/9 activatable peptide probes.
van Duijnhoven SM; Robillard MS; Hermann S; Kuhlmann MT; Schäfers M; Nicolay K; Grüll H
Mol Pharm; 2014 May; 11(5):1415-23. PubMed ID: 24641497
[TBL] [Abstract][Full Text] [Related]
20. HPMA copolymer conjugates with reduced anti-CD20 antibody for cell-specific drug targeting. I. Synthesis and in vitro evaluation of binding efficacy and cytostatic activity.
Etrych T; Strohalm J; Kovár L; Kabesová M; Ríhová B; Ulbrich K
J Control Release; 2009 Nov; 140(1):18-26. PubMed ID: 19632282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
